Pyxis Oncology Inc (PYXS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.33 (-2.35%), Market cap $0.17B, 52-week low–high $1.04 ~ $5.34.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat
Financial statements, price targets, institutional (13F) holdings and related news for Pyxis Oncology Inc are updated in real time on BlackAll Trade.
Pyxis Oncology Inc trades at $3.33 (-2.35%). Real-time quotes and charts are available on BlackAll Trade.
Pyxis Oncology Inc has a market cap of about $0.17B.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigation